<DOC>
	<DOCNO>NCT00369395</DOCNO>
	<brief_summary>This Phase 2 , multicenter , research study determine effect investigational drug call volociximab metastatic melanoma . The purpose study compare clinical benefit safety volociximab . Pharmacokinetics mechanism action also evaluate .</brief_summary>
	<brief_title>A Study Volociximab Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Must give write informed consent authorization require local law ( e.g. , Protected Health Information [ PHI ] ) . 2 . Aged &gt; =18 year old time inform consent . 3 . Stage III Stage IV unresectable melanoma document progression follow recent prior melanoma therapy . 4 . Must fail least 1 prior therapy metastatic disease . 5 . Must least 2 cutaneous , subcutaneous , nodal metastasis safely accessible pre treatment post treatment biopsy . 6 . Must agree pretreatment posttreatment biopsy tumor lesion ( subject Stage 1 ) . 7 . Must least 1 measurable target lesion CT/MRI assessment , accord RECIST criterion . 8 . ECOG Performance Status &lt; =1 . 9 . Acceptable laboratory result 10 . Life expectancy &gt; =12 week . 11 . Male subject female subject child bear potential must willing practice effective contraception study willing able continue contraception 4 month last infusion study treatment . Exclusion Criteria 1 . Subjects active malignancy addition metastatic melanoma . 2 . CNS metastases , unless stable least 2 month follow definitive local therapy ( surgery , stereotactic radiation ) . Subjects may require treatment steroid anticonvulsant . 3 . History significant medical condition , include cardiovascular , pulmonary , neurologic , autoimmune disease ; active infection ( e.g. , bacterial fungal ) ; psychiatric condition within 6 month Day 1 4 . History hepatitis B C. 5 . Known history HIV infection AIDS . 6 . History thromboembolic cerebrovascular event , stroke , transient ischemic attack , deep vein thrombosis , bleed disorder within 12 month prior Day 1 . 7 . Prior radiation therapy , chemotherapy , hormonal therapy , immunotherapy melanoma within 4 week prior Day 1 . 8 . Previous exposure volociximab . 9 . Aspirin , high dose warfarin , heparin use . ( Note : Aspirin &lt; =81 mg/day , lowdose warfarin 1 mg/day lowdose heparin IV catheter patency allow . ) 10 . Major surgery within 4 week prior Day 1 . 11 . Requirement immunosuppression , and/or systemic steroid therapy . 12 . Investigational therapy within 4 week prior Day 1 4 half life prior investigational drug ( whichever longer ) . 13 . Known hypersensitivity murine chimeric antibody . 14 . Any condition , opinion Investigator , make subject unsuitable study participation . 15 . Female subject pregnant currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>melanoma</keyword>
	<keyword>antibody</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>volociximab</keyword>
</DOC>